CINECA IRIS Institutional Research Information System

BUGIANESI, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 40.431
NA - Nord America 33.400
EU - Europa 27.350
SA - Sud America 2.676
AF - Africa 952
OC - Oceania 830
Continente sconosciuto - Info sul continente non disponibili 60
Totale 105.699
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.454
CN - Cina 24.609
IT - Italia 5.093
DE - Germania 3.673
GB - Regno Unito 2.909
JP - Giappone 2.867
IN - India 2.549
FR - Francia 2.347
SG - Singapore 1.997
ES - Italia 1.982
KR - Corea 1.582
SE - Svezia 1.579
IE - Irlanda 1.568
CA - Canada 1.419
BR - Brasile 1.342
MX - Messico 1.326
HK - Hong Kong 1.236
NL - Olanda 1.054
TR - Turchia 1.029
TW - Taiwan 1.022
FI - Finlandia 785
PL - Polonia 782
UA - Ucraina 779
AU - Australia 757
AT - Austria 651
GR - Grecia 597
VN - Vietnam 573
ID - Indonesia 572
DK - Danimarca 539
RU - Federazione Russa 514
BE - Belgio 473
EG - Egitto 442
RO - Romania 431
PT - Portogallo 395
CH - Svizzera 365
IR - Iran 351
TH - Thailandia 322
IL - Israele 310
PE - Perù 310
CO - Colombia 296
CL - Cile 269
AR - Argentina 255
CZ - Repubblica Ceca 213
PK - Pakistan 209
SA - Arabia Saudita 181
PH - Filippine 148
MY - Malesia 143
EC - Ecuador 138
NO - Norvegia 100
ZA - Sudafrica 89
AE - Emirati Arabi Uniti 78
BD - Bangladesh 76
HU - Ungheria 76
HR - Croazia 74
LK - Sri Lanka 73
NZ - Nuova Zelanda 66
LB - Libano 59
MO - Macao, regione amministrativa speciale della Cina 57
IQ - Iraq 56
RS - Serbia 53
DZ - Algeria 52
SK - Slovacchia (Repubblica Slovacca) 50
QA - Qatar 46
BG - Bulgaria 45
EU - Europa 45
KZ - Kazakistan 45
LT - Lituania 44
MN - Mongolia 39
NG - Nigeria 38
VE - Venezuela 38
PA - Panama 37
MA - Marocco 35
SD - Sudan 33
JO - Giordania 29
UZ - Uzbekistan 28
TN - Tunisia 27
ET - Etiopia 26
GT - Guatemala 26
SI - Slovenia 26
CY - Cipro 25
LY - Libia 25
PS - Palestinian Territory 25
SN - Senegal 25
CM - Camerun 24
DO - Repubblica Dominicana 23
KE - Kenya 23
LU - Lussemburgo 23
BY - Bielorussia 21
CU - Cuba 20
MD - Moldavia 20
CR - Costa Rica 19
PR - Porto Rico 19
GH - Ghana 18
MK - Macedonia 18
BA - Bosnia-Erzegovina 15
IS - Islanda 15
KW - Kuwait 15
NI - Nicaragua 15
SV - El Salvador 15
LV - Lettonia 14
Totale 105.420
Salva come PNG Salva come JPEG
Città #
Beijing 3.396
Shanghai 2.301
Chandler 1.911
Dublin 1.523
Fairfield 1.523
Singapore 1.503
Guangzhou 1.465
Houston 1.399
Redwood City 1.270
Nanjing 1.167
Ann Arbor 1.090
Ashburn 1.029
Santa Clara 879
Hangzhou 863
Wilmington 851
Woodbridge 785
Seattle 708
Tokyo 708
Dearborn 688
Wuhan 668
Torino 611
Chengdu 580
Villeurbanne 564
New York 561
Jacksonville 543
Cambridge 538
Taipei 522
London 470
Ottawa 449
Columbus 445
Princeton 435
Medford 424
Pisa 412
Chongqing 404
Vienna 394
Shenyang 383
Jinan 354
Los Angeles 350
Changsha 348
Warsaw 347
Istanbul 338
Jakarta 337
Zhengzhou 337
Boston 333
Duncan 325
Seoul 321
Rome 315
Turin 314
Milan 306
Tianjin 296
Nyköping 294
Dong Ket 275
Central 269
Hefei 260
Barcelona 258
Madrid 255
Athens 237
Changchun 232
Lima 232
Delhi 218
Fuzhou 215
San Diego 205
Toronto 203
Hong Kong 202
Paris 201
Santiago 198
São Paulo 198
Fremont 195
Copenhagen 193
Frankfurt am Main 190
Mumbai 190
Helsinki 182
Sydney 177
Xi'an 176
Shenzhen 173
Hyderabad 170
Bengaluru 168
Kunming 168
Amsterdam 164
Central District 158
Nanchang 154
New Delhi 154
Boardman 149
Munich 149
Nanning 149
Chicago 148
San Jose 145
Berlin 143
Harbin 141
Rochester 137
Washington 136
Brussels 135
Xian 135
Bangkok 125
Ankara 121
Chennai 120
Mexico City 120
Kolkata 116
Philadelphia 116
Valencia 116
Totale 47.048
Salva come PNG Salva come JPEG
Nome #
Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention 22.022
Liver cancer: Connections with obesity, fatty liver, and cirrhosis 7.367
Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis 7.351
Nonalcoholic fatty liver disease 5.610
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 4.957
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis 3.843
Advancing the global public health agenda for NAFLD: a consensus statement 1.869
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 1.628
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 1.437
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults 1.285
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 1.108
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease 1.062
Preparing for the NASH Epidemic: A Call to Action 944
NASH in lean individuals 909
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry 821
Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? 727
qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis 687
Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease 684
MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease 675
Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. 674
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease 609
An extended fatty liver index to predict non-alcoholic fatty liver disease. 562
A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD 554
From the metabolic syndrome to NAFLD or vice versa? 551
Should we undertake surveillance for HCC in patients with NAFLD? 541
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 534
FibroGENE: A gene-based model for staging liver fibrosis 531
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study 514
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening 487
Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease 487
Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause? 473
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes 462
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 460
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients with Nonalcoholic Fatty Liver Disease 398
A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR 391
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 389
A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease 381
Risk of non alcoholic steatohepatitis and fibrosis in patients with non alcoholic fatty liver disease and low visceral adiposity 357
Non-invasive score system for fibrosis in chronic hepatitis: Proposal for a model based on biochemical, FibroScan and ultrasound data 354
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates 339
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease 332
Management of non-alcoholic fatty liver disease 310
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents 289
Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists 279
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. 276
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis 269
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease 267
[Non-alcoholic fatty liver disease (NAFLD)] 263
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis 239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action? 234
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 229
Insulin resistance in nonalcoholic fatty liver disease. 221
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 219
HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients 216
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease 204
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease 204
Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice 199
AISF position paper on liver disease and pregnancy. 197
Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis 196
Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. 196
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 192
Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study 191
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease 190
Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis 180
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 179
Hypoxia-inducible factor 2alpha drives the progression of experimental non-alcoholic fatty liver disease by stimulating hepatocyte production of histidine rich glycoprotein 179
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 176
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 174
How to diagnose NAFLD in 2016 173
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 173
Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation 171
A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification 171
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 167
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 165
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 165
Non-alcoholic fatty liver disease and extra-hepatic cancers 163
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 161
Metabolic Syndrome and Severity of Fibrosis in Nonalcoholic Fatty Liver Disease: An Age-Dependent Risk Profiling Study 160
A "systems medicine" approach to the study of non-alcoholic fatty liver disease. 156
Undernutrition, risk of malnutrition and obesity in gastroenterological patients: A multicenter study 156
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 155
Hepatic conversion of amino nitrogen to urea nitrogen in hypothyroid patients and upon L-thyroxine therapy. 154
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis 153
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 151
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 151
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 151
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 149
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis 149
Increased epicardial fat and early signs of impaired diastolic and systolic left ventricular function in non-diabetic, non-dyslipidemic, normotensive patients with Nonalcoholic Fatty Liver Disease 144
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 144
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 141
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) 141
Metabolic handling of an oral fat load in NAFLD patients. 138
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 137
Risk factors for metabolic syndrome after liver transplantation: what has changed over time 137
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 136
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 136
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 134
Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with Non Alcoholic Fatty Liver Disease independent of diabetes, hypertension and dyslipidemia 134
In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease 134
Totale 86.184
Salva come PNG Salva come JPEG
Categoria #
all - tutte 199.610
article - articoli 0
book - libri 0
conference - conferenze 33.501
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 233.111
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.578 0 0 0 0 0 1.372 1.005 943 1.277 1.184 1.005 792
2020/202115.769 902 948 964 1.164 1.713 1.384 1.444 1.025 1.631 1.601 1.421 1.572
2021/202215.741 1.021 1.158 1.212 1.451 1.338 1.177 1.378 1.329 1.557 1.116 1.518 1.486
2022/202316.608 1.267 1.142 881 1.288 1.292 2.248 1.520 1.349 1.584 1.163 1.240 1.634
2023/202422.060 1.942 1.968 1.884 2.127 2.206 2.016 1.757 2.137 709 1.548 1.893 1.873
2024/202512.373 1.583 1.895 1.811 2.339 3.141 1.604 0 0 0 0 0 0
Totale 107.982